170 related articles for article (PubMed ID: 11400962)
1. The breast cancer patient with multiple sentinel nodes: when to stop?
McCarter MD; Yeung H; Fey J; Borgen PI; Cody HS
J Am Coll Surg; 2001 Jun; 192(6):692-7. PubMed ID: 11400962
[TBL] [Abstract][Full Text] [Related]
2. Clinicopathologic analysis of sentinel lymph node mapping in early breast cancer.
Choi SH; Barsky SH; Chang HR
Breast J; 2003; 9(3):153-62. PubMed ID: 12752622
[TBL] [Abstract][Full Text] [Related]
3. Guidelines for sentinel node biopsy and lymphatic mapping of patients with breast cancer.
Cox CE; Pendas S; Cox JM; Joseph E; Shons AR; Yeatman T; Ku NN; Lyman GH; Berman C; Haddad F; Reintgen DS
Ann Surg; 1998 May; 227(5):645-51; discussion 651-3. PubMed ID: 9605656
[TBL] [Abstract][Full Text] [Related]
4. Sentinel lymph node biopsy for breast cancer: impact of the number of sentinel nodes removed on the false-negative rate.
Wong SL; Edwards MJ; Chao C; Tuttle TM; Noyes RD; Carlson DJ; Cerrito PB; McMasters KM
J Am Coll Surg; 2001 Jun; 192(6):684-9; discussion 689-91. PubMed ID: 11400961
[TBL] [Abstract][Full Text] [Related]
5. Factors affecting failed localisation and false-negative rates of sentinel node biopsy in breast cancer--results of the ALMANAC validation phase.
Goyal A; Newcombe RG; Chhabra A; Mansel RE;
Breast Cancer Res Treat; 2006 Sep; 99(2):203-8. PubMed ID: 16541308
[TBL] [Abstract][Full Text] [Related]
6. Sentinel lymph node pressure in breast cancer.
Nathanson SD; Mahan M
Ann Surg Oncol; 2011 Dec; 18(13):3791-6. PubMed ID: 21626079
[TBL] [Abstract][Full Text] [Related]
7. High isotope counts and sentinel node positivity in patients with melanoma.
Jacobs IA; Chang CK; DasGupta TK; Salti G
Arch Surg; 2003 Jan; 138(1):63-6; discussion 67. PubMed ID: 12511153
[TBL] [Abstract][Full Text] [Related]
8. Axillary lymph node recurrence after sentinel lymph node biopsy performed using a combination of indocyanine green fluorescence and the blue dye method in early breast cancer.
Inoue T; Nishi T; Nakano Y; Nishimae A; Sawai Y; Yamasaki M; Inaji H
Breast Cancer; 2016 Mar; 23(2):295-300. PubMed ID: 25348937
[TBL] [Abstract][Full Text] [Related]
9. Sentinel node biopsy in ductal carcinoma in situ patients.
Pendas S; Dauway E; Giuliano R; Ku N; Cox CE; Reintgen DS
Ann Surg Oncol; 2000; 7(1):15-20. PubMed ID: 10674443
[TBL] [Abstract][Full Text] [Related]
10. Concordance of peritumoral technetium 99m colloid and subareolar blue dye injection in breast cancer sentinel lymph node biopsy.
Kargozaran H; Shah M; Li Y; Beckett L; Gandour-Edwards R; Schneider PD; Khatri VP
J Surg Res; 2007 Nov; 143(1):126-9. PubMed ID: 17950081
[TBL] [Abstract][Full Text] [Related]
11. Intradermal radioisotope is superior to peritumoral blue dye or radioisotope in identifying breast cancer sentinel nodes.
Lin KM; Patel TH; Ray A; Ota M; Jacobs L; Kuvshinoff B; Chung M; Watson M; Ota DM
J Am Coll Surg; 2004 Oct; 199(4):561-6. PubMed ID: 15454139
[TBL] [Abstract][Full Text] [Related]
12. Practical guidelines for optimal gamma probe detection of sentinel lymph nodes in breast cancer: results of a multi-institutional study. For the University of Louisville Breast Cancer Study Group.
Martin RC; Edwards MJ; Wong SL; Tuttle TM; Carlson DJ; Brown CM; Noyes RD; Glaser RL; Vennekotter DJ; Turk PS; Tate PS; Sardi A; Cerrito PB; McMasters KM
Surgery; 2000 Aug; 128(2):139-44. PubMed ID: 10922983
[TBL] [Abstract][Full Text] [Related]
13. Is the "10% rule" equally valid for all subsets of sentinel-node-positive breast cancer patients?
Chung A; Yu J; Stempel M; Patil S; Cody H; Montgomery L
Ann Surg Oncol; 2008 Oct; 15(10):2728-33. PubMed ID: 18688679
[TBL] [Abstract][Full Text] [Related]
14. Intraoperative subareolar injection of 99mTc-labeled sulfur colloid results in consistent sentinel lymph node identification.
Zogakis TG; Wetherille RE; Christensen RD; Ose KJ; Friedman JD; Colbert M; Svendsen CA; Sanan OK; Tuttle TM
Ann Surg Oncol; 2005 Feb; 12(2):167-72. PubMed ID: 15827798
[TBL] [Abstract][Full Text] [Related]
15. Retrospective analysis of sentinel node localization in multifocal, multicentric, palpable, or nonpalpable breast cancer.
Kumar R; Jana S; Heiba SI; Dakhel M; Axelrod D; Siegel B; Bernik S; Mills C; Wallack M; Abdel-Dayem HM
J Nucl Med; 2003 Jan; 44(1):7-10. PubMed ID: 12515869
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of lymph node status in male breast cancer patients: a role for sentinel lymph node biopsy.
Albo D; Ames FC; Hunt KK; Ross MI; Singletary SE; Kuerer HM
Breast Cancer Res Treat; 2003 Jan; 77(1):9-14. PubMed ID: 12602900
[TBL] [Abstract][Full Text] [Related]
17. Comparison of [(99m)Tc]tilmanocept and filtered [(99m)Tc]sulfur colloid for identification of SLNs in breast cancer patients.
Baker JL; Pu M; Tokin CA; Hoh CK; Vera DR; Messer K; Wallace AM
Ann Surg Oncol; 2015 Jan; 22(1):40-5. PubMed ID: 25069859
[TBL] [Abstract][Full Text] [Related]
18. Intradermal isotope injection: a highly accurate method of lymphatic mapping in breast carcinoma.
Boolbol SK; Fey JV; Borgen PI; Heerdt AS; Montgomery LL; Paglia M; Petrek JA; Cody HS; Van Zee KJ
Ann Surg Oncol; 2001; 8(1):20-4. PubMed ID: 11206219
[TBL] [Abstract][Full Text] [Related]
19. A trend analysis of the relative value of blue dye and isotope localization in 2,000 consecutive cases of sentinel node biopsy for breast cancer.
Derossis AM; Fey J; Yeung H; Yeh SD; Heerdt AS; Petrek J; VanZee KJ; Montgomery LL; Borgen PI; Cody HS
J Am Coll Surg; 2001 Nov; 193(5):473-8. PubMed ID: 11708502
[TBL] [Abstract][Full Text] [Related]
20. Sentinel node biopsy in primary breast cancer: radioactive detection and metastatic disease.
Wada N; Sakemura N; Imoto S; Hasebe T; Ochiai A; Moriyama N
Eur J Surg Oncol; 2007 Aug; 33(6):691-5. PubMed ID: 17258879
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
